Shopping Cart
- Remove All
- Your shopping cart is currently empty
Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $516 | In Stock | |
10 mg | $828 | In Stock | |
25 mg | $1,230 | In Stock | |
50 mg | $1,650 | In Stock |
Description | Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohn's disease research. |
Targets&IC50 | IL-23:0.138 nM (Kd) |
In vitro | Brazikumab is a human IgG2 monoclonal antibody that binds to the p19 subunit with high affinity and has a KD of 0.138 nM against human IL-23. Brazikumab inhibits the binding of recombinant and natural IL-23 to receptors that are stably expressed in COS cells with IC50 of 188 and 284 pM, respectively. Brazikumab inhibits in vitro production of IFN-γ in NK cells stimulated by human natural or recombinant IL-23 (bound to IL-18) with IC50 of 238 and 93 pM, respectively. [1] |
Alias | MEDI2070, MEDI 2070, AMG139, AMG 139 |
Cas No. | 1610353-18-8 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.